Phosphodiesterases as Therapeutic Targets for Huntington’s Disease

E-ISSN： 1873-4286|21|3|365-377

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.21, Iss.3, 2015-01, pp. : 365-377

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel therapeutic targets for Huntington’s disease

By Hannan Anthony J

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 4, 2005-08 ,pp. : 639-650

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic strategies in Huntington’s disease

By Alberch Jordi Canals Josep M Pérez-Navarro Esther

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 4, 2003-04 ,pp. : 449-465

Informa Healthcare

Access to resources Recommend Favorite

GABA signalling: therapeutic targets for epilepsy, Parkinson’s disease and Huntington’s disease

By Kleppner S.R. Tobin A.J.

Expert Opinion on Therapeutic Targets, Vol. 5, Iss. 2, 2001-04 ,pp. : 219-239

Informa Healthcare

Access to resources Recommend Favorite

Neuroprotection in Huntington;s Disease

Letters in Drug Design & Discovery, Vol. 2, Iss. 2, 2005-03 ,pp. : 143-147

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Oxidative Stress in Huntington’s Disease: Are Antioxidants Good Therapeutic Candidates?

Current Drug Targets, Vol. 15, Iss. 4, 2014-04 ,pp. : 454-468

Bentham Science Publishers

Access to resources Recommend Favorite